Turn Therapeutics Expands Executive Team with New VP Appointment
Turn Therapeutics Inc. (NASDAQ: TTRX), a pioneer in biotechnology focused on developing innovative therapies for dermatology, advanced wound care, and infectious diseases, is pleased to announce the appointment of Andrew Scott as the new Vice President of Corporate Communications. Mr. Scott will take charge of investor relations, capital market strategies, and corporate communications, playing a pivotal role in promoting the company’s partnerships and licensing initiatives.
Strategic Leadership and Growth Potential
Bradley Burnam, the Founder and Chief Executive Officer of Turn Therapeutics, expressed enthusiasm about Andrew's arrival, stating, “His role comes at a critical time as we embark on an exciting growth journey post our public listing. With his extensive experience, Andrew will significantly enhance our communication strategies, ensuring that our narrative reaches the appropriate channels while we work towards key milestones like the completion of our Phase 2 clinical program.” This appointment aligns with the company’s vision to strengthen its presence in the market and enhance investor engagement.
Expertise in Capital Markets
Andrew Scott brings over 30 years of experience in capital markets and corporate finance to Turn Therapeutics. Prior to his new position, he served as the Managing Director of Investment Banking at ThinkEquity LLC, where he honed his skills in strategic financial planning and execution. His previous role as Vice President of Business Development at Fortress Biosciences, Inc. allowed him to successfully engage in raising approximately $3 billion through a wide spectrum of transactions within the life sciences sector. He holds a Bachelor of Business Administration in Accounting from Pace University, showcasing his solid educational foundation.
About Turn Therapeutics
Turn Therapeutics serves as a forward-thinking biotechnology company dedicated to developing and commercializing cutting-edge products in dermatology, wound care, and infectious disease management. Over the years, the company has achieved three FDA clearances for its proprietary formulations and is currently advancing late-stage clinical programs focusing on eczema and onychomycosis. Additionally, their initiatives for the development of thermostable vaccine delivery systems are directed at benefiting underserved populations globally, aligning with their mission of health innovation.
Connecting with Turn Therapeutics
For inquiries regarding investor relations, you can reach out to Monique Kosse, Managing Director at Gilmartin Group through her email. The company emphasizes open lines of communication, ensuring that stakeholders have access to essential information related to its progress and initiatives. Furthermore, media-related questions can be directed to their dedicated media contact email, emphasizing Turn Therapeutics' commitment to transparency and engagement.
Frequently Asked Questions
What is the role of Andrew Scott at Turn Therapeutics?
Andrew Scott has been appointed as Vice President of Corporate Communications, focusing on investor relations and capital market strategies.
How will Andrew Scott's experience benefit Turn Therapeutics?
With over 30 years in capital markets and corporate finance, Andrew has the expertise to enhance investor engagement and communication strategies, aligning with the company’s growth objectives.
What areas does Turn Therapeutics focus on?
Turn Therapeutics specializes in therapies for dermatological issues, advanced wound care, and infectious diseases, aiming to innovate in these critical healthcare areas.
What are Turn Therapeutics' recent achievements?
The company has received three FDA clearances for its proprietary products and is advancing clinical programs targeting eczema and onychomycosis.
How can I contact Turn Therapeutics for investor-related inquiries?
Interested parties can contact Monique Kosse, Managing Director at Gilmartin Group, via her email listed in the company's investor relations section.
